Anti-Mouse IFNß [Clone MIB-5E9.1] — Purified in vivo GOLD™ Functional Grade

Clone MIB-5E9.1 is a monoclonal antibody specific for mouse interferon-beta (IFN-?), and in in vivo mouse studies, it is primarily used to neutralize or block endogenous IFN-? activity to assess its functional role in various biological processes. The antibody is validated for functional (in vivo) use, as well as for techniques such as Western blotting.

In practice:

• Functional In Vivo Blockade: MIB-5E9.1 is administered to living mice, where it binds specifically to mouse IFN-? and prevents it from interacting with its receptor. This allows researchers to study the effects of IFN-? depletion on processes such as immune responses, antiviral defense, inflammation, and disease models.
• Experimental Example: In studies of glioma immunity, MIB-5E9.1 has been used to immunodeplete IFN-?, enabling analysis of how loss of IFN-? alters tumor growth and immune cell activity. Mice treated with anti-IFN-? antibody show altered tumor control, confirming a functional role for IFN-? in these settings.
• Other Applications: While its main in vivo role is functional blockade, MIB-5E9.1 can also be used ex vivo or in vitro to detect mouse IFN-? by immunoblotting (Western blot), though this is not an in vivo application.

In summary, clone MIB-5E9.1 is used in vivo in mice to neutralize IFN-?, enabling mechanistic dissection of interferon-beta-dependent activities during infection, tumor growth, and immunological challenges. The antibody is produced in functional, in vivo-grade formulations with low endotoxin levels, optimized for safe administration in animal studies.

The correct storage temperature for the sterile packaged clone MIB-5E9.1 antibody is undiluted at 2°C to 8°C (refrigerator temperature). This means you should keep the product in a standard laboratory refrigerator and do not freeze it.

Additional context and supporting information:

• Multiple sources specify "undiluted at 4°C" or "2–8°C" as correct for storage stability.
• For longer-term storage beyond one month, some suppliers recommend aliquoting aseptically to minimize contamination and maintain activity.
• Storage at temperatures outside 2–8°C (e.g., freezing or room temperature) is not recommended as it can degrade antibody function.

Key points:

• 2–8°C, undiluted, sterile is the standard for short-term storage.
• Do not freeze the antibody unless otherwise specified by the manufacturer.
• If the product contains no preservative, handle under aseptic conditions and avoid repeated freeze/thaw cycles.

Commonly used antibodies and proteins alongside MIB-5E9.1 (an anti-mouse IFN-? monoclonal antibody) in the literature include other cytokine and checkpoint antibodies, particularly those involved in immune cell activation and inhibition.

Key co-used antibodies/proteins:

• Anti-B7H1 (Clone 10F.9G2): Frequently used as a blocking antibody to study the role of the immune checkpoint molecule PD-L1 (B7H1) in dendritic cells (DCs) and T cell activation.
• LPS (Lipopolysaccharide): Not an antibody, but used as a stimulant to activate dendritic cells for studies involving IFN-? and immune modulation.
• OVA peptide (SIINFEKL): Used for antigen-specific stimulation in T cell proliferation assays. While not an antibody, it is a commonly co-applied reagent in the context of these experiments.
• Anti-IFN-? ELISpot/flow cytometry reagents: Used to assess downstream T cell responses such as IFN-? production or CTL priming after treatment with MIB-5E9.1 and other agents.
• BrdU Cell Proliferation Assay reagents: These are used to measure T cell proliferation after stimulation with DCs treated with MIB-5E9.1 and/or other antibodies.

In representative protocols, MIB-5E9.1 is paired most often with antibodies targeting immune checkpoints (such as PD-1/PD-L1 pathways), other cytokines like IFN-?, as well as functional readouts such as BrdU and ELISpot assays for cellular proliferation and activation.

Other potentially co-used markers (dependent on the specific research context) include:

• CD markers (e.g., CD80, CD86, CD3, CD4, CD8) for detailed immune profiling by flow cytometry.
• Anti-mouse IFN-? or IFNAR antibodies, given their involvement in type I interferon signaling.

This pattern is supported by experimental descriptions in the literature, where MIB-5E9.1 is not typically used in isolation but as part of a broader immunological panel to dissect the interplay between type I interferon signaling and immune checkpoint regulation.

Based on the available search results, there is no direct evidence from primary scientific literature outlining specific research findings or experimental outcomes directly attributed to the use of clone MIB-5E9.1, a monoclonal antibody targeting mouse interferon-beta (IFN-?). Instead, the available references describe the properties, characteristics, and recommended applications of this antibody, but do not detail novel biological insights, mechanisms, or key experimental results generated using the antibody in published studies.

Summary of Available Information

Clone MIB-5E9.1 is a well-characterized Armenian hamster monoclonal antibody that specifically recognizes mouse IFN-?. Its main applications in the cited documents include:

• Western blotting: The antibody is recommended for detecting mouse IFN-? in immunoblot analyses, with a suggested working concentration of 1–10 ?g/ml.
• Neutralization assays: The antibody is also recommended for neutralizing murine IFN-? bioactivity in functional assays, though the optimal dilution must be determined by the user for specific applications.
• Antibody production: The antibody is purified using multi-step affinity chromatography methods, ensuring high specificity and consistency.

No key experimental findings—such as novel discoveries about IFN-? signaling, cellular responses, or disease mechanisms—are described in the available pages as originating from studies using this clone. There are no peer-reviewed publications or detailed experimental results cited that use MIB-5E9.1 to uncover new biological functions of IFN-? or to dissect molecular pathways.

Additional Context

The sources describe general background on IFN-?, including its classification as a type I interferon, its signaling through the IFNAR1/2 receptors, and its roles in antiviral defense, immune cell modulation, and potential therapeutic applications in diseases like multiple sclerosis and rheumatoid arthritis. However, these are not findings attributable to clone MIB-5E9.1 itself, but rather general information about IFN-? biology.

Conclusion

There are no key scientific findings linked directly to the use of clone MIB-5E9.1 in the cited literature. The available documents focus on the antibody’s technical specifications, recommended uses for detection and neutralization of mouse IFN-?, and general facts about IFN-? biology—not on original research or discoveries made possible by this clone. For detailed experimental results using this antibody, a direct search of primary research articles citing MIB-5E9.1 would be necessary.